Responsible for all pre-launch commercial projects for the first cell therapy for melanoma and cervical cancer. Delivered the US and EU commercial strategy, go-to-market plans, customer engagement plans, sales force sizing and forecasts. Established the commercial organization and recruited top talent for business analytics, commercial operations, managed markets and marketing functions. Initiated company-wide efforts to identify and onboard cell therapy accounts at over 50 key cancer centers.

Implemented alliance management functions with US and Japanese partners for commercialized products to ensure optimal outcomes for Gilead. Spearheaded company-wide initiative to secure sole ownership of a multi-billion-dollar HIV product from a large-pharma JV partner. Navigated a complex partner relationship to enable the termination of license agreements with a Japanese pharmaceutical company for 6 HIV products in Japan.

Developed market access plans and field payer promotional materials for key payer segments for the HCV franchise. Served as the US market access liver disease and pipeline therapeutic lead to drive strategic insights to optimize coverage across multiple assets. Established the US payer strategy, value messaging and marketing materials for two product launches.

Championed the global launch of Gilead’s HCV franchise and served as the global commercial leader responsible for all liver disease related products. Created all global brand campaigns, launch plans, and led readiness activities in the US, EU, and Asia for the launches of SOVALDI and HARVONI. Provided critical ongoing support for Japan Gilead KK affiliate and regional Asia teams. Delivered multiple three-year Global Commercial Strategic Plans, Long Range Forecasts, and Portfolio Review.

Delivered oversight for market preparation for HCV and NASH programs. Worked collaboratively to implement commercialization plan and strategy development in coordination with regional and cross-functional teams. Directly responsible for the business case supporting the $11 billion acquisition of Pharmasset. Served as the commercial lead on all HCV and NASH development programs from pre-IND through to launch.